Project Grant F30CA294601
Award Date
1/8/25
Completion Date
8/31/27
Dollars Obligated
$108K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a Project Grant in the amount of $145,336 to the Sloan-Kettering Institute for Cancer Research located in New York. The grant, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors," will fund research focused on reprogramming hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven...
The National Cancer Institute (NCI), a component of the Department of Health and Human Services National Institutes of Health, awarded a $101,340 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Regents of the University of Michigan. The award will fund research to investigate the role of the MS4A14 protein in regulating macrophage activation and antigen presentation, with the goal of improving immunotherapy response in cancer patients. The research...
The National Cancer Institute (NCI), under the federal Cancer Research Manpower Grant Program (CFDA 93.398), awarded a $159,304 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) located in Boston, Massachusetts. The grant aims to identify novel regulators of live cell phagocytosis by macrophages and determine the extent to which this process can destroy tumor cells in vivo. The research will focus on defining the role of deubiquitinases in regulating macrophage surface receptors...
This Project Grant award of $499,744 from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) supports research to understand the role of the signaling protein STAT5 in regulating tumor-associated macrophage function and its impact on breast cancer growth and metastasis. The research aims to: 1) define the effects of deleting STAT5 in macrophages on mammary tumor progression, 2) elucidate the mechanisms by which STAT5 modulation in macrophages impacts the tumor...
The National Cancer Institute (NCI) awarded a $162,080 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The Johns Hopkins University. The grant supports a study to visualize B cell infiltration and aggregation within the tumor microenvironment. Specifically, the study uses transgenic mouse models and intravital microscopy to investigate how high endothelial venules facilitate B cell entry into tumors and the formation of tertiary lymphoid structures,...
The National Cancer Institute (NCI) awarded a $1,035,236 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to study the role of TREM1, an immune receptor, in leukemia-associated macrophages (LAMs) and their interaction with leukemic stem cells. The research aims to 1) examine the function of TREM1 in LAMs and their contribution to leukemia development, and 2) investigate the interactions between TREM1-positive LAMs and leukemic stem cells. The project...
This $393,750.00 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) will fund a 5-year research project to explore the fundamental cellular mechanisms driving cellular senescence in macrophages. The key objectives of this research project are to gain a deeper understanding of the cellular and molecular mechanisms underlying senescent macrophage biology. This includes investigating the roles...
The National Cancer Institute (NCI) awarded a $149,804 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Pittsburgh. The award will fund research to investigate the impact of the LAG3 protein on CD8+ T cell motility and migration in the context of cancer immunotherapy. The project aims to elucidate the mechanism by which LAG3 restricts T cell motility and determine if reduced motility impacts T cell infiltration into the tumor microenvironment. The...
This $1,088,500 Project Grant was awarded on September 20, 2024 by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant supports research to enhance the cancer-killing abilities of engineered macrophage (CAR-M) cellular immunotherapies, with the goal of overcoming limitations of current chimeric antigen receptor T-cell (CAR-T) therapies. The project, conducted by the University of California, Santa Barbara, aims to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $218,089 to the University of California, Santa Barbara to develop and evaluate a novel Chimeric Antigen Receptor Macrophage (CAR-M) immunotherapy targeting triple-negative breast cancer (TNBC). The key goals are to: 1) Evaluate the specificity, efficacy, and impact on angiogenesis of an anti-CSPG4 Rac-enhanced CAR-M (RACE-CAR-M) therapy using in vivo chicken chorioallantoic membrane...